This investigation aimed at evaluating the efficiency of micro and nanoclays as a low-cost material for the removal of crystal violet (CV) dye from an aqueous solution. The impacts of various factors (contact time, pH, adsorbent dosage, temperature, initial dye concentration) on the adsorption process have been taken into consideration. Six micro and nanoclay samples were obtained by treating clay materials collected from different locations in the Albaha region, Saudi Arabia. Out of the six tested micro and nanoclays materials, two (NCQ1 and NCQ3) were selected based on the highest adsorption efficiency for complete experimentation. The morphology and structure of the selected micro and nanoclay adsorbents were characterized by various techniques: SEM-EDX, FTIR, XRF, XRD, and ICP-MS. The XRF showed that the main oxides of both nanoclays were SiO₂, Al₂O₃, Fe₂O₃, K₂O, CaO, and MgO, and the rest were impurities. All the parameters affecting the adsorption of CV dye were optimized in a batch system, and the optimized working conditions were an equilibrium time of 120 min, a dose of 30 mg, a temperature of 25 °C, and an initial CV concentration of 400 mg/L. The equilibrium data were tested using nonlinear isotherm and kinetic models, which showed that the Freundlich isotherm and pseudo-second-order kinetics gave the best fit with the experimental data, indicating a physico-chemical interaction occurred between the CV dye and both selected micro and nanoclay surfaces. The maximum adsorption capacities of NCQ1 and NCQ3 adsorbents were 206.73 and 203.66 mg/g, respectively, at 25 °C. The thermodynamic factors revealed that the CV dye adsorption of both micro and nanoclays was spontaneous and showed an exothermic process. Therefore, the examined natural micro and nanoclays adsorbents are promising effective adsorbents for the elimination of CV dye from an aqueous environment.

A library of novel naproxen based 1,3,4-oxadiazole derivatives (8–16 and 19–26) has been synthesized and screened for cytotoxicity as EGFR inhibitors. Among the synthesized hybrids, compound2-(4-((5-((S)-1-(2-methoxynaphthalen-6-yl)ethyl)-1,3,4-oxadiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)phenol(15) was the most potent compound against MCF-7 and HepG2cancer cells with IC₅₀ of 2.13 and 1.63 µg/mL, respectively, and was equipotent to doxorubicin (IC₅₀ 1.62 µg/mL) towards HepG2. Furthermore, compound 15 inhibited EGFR kinase with IC₅₀ 0.41 μM compared to standard drug Erlotinib (IC₅₀ 0.30 μM). The active compound induces a high percentage of necrosis towards MCF-7, HePG2 and HCT 116 cells. The docking studies, DFT and MEP also supported the biological data. These results demonstrated that these synthesized naproxen hybrids have EGFR inhibition effects and can be used as leads for cancer therapy.

A library of 1,2,3-triazole-incorporated thymol-1,3,4-oxadiazole derivatives (6–18) hasbeen synthesized and tested for anticancer and antimicrobial activities. Compounds 7, 8, 9, 10, and 11 exhibited significant antiproliferative activity. Among these active derivatives, compound 2-(4-((5-((2-isopropyl-5-methylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)phenol (9) was the best compound against all three tested cell lines, MCF-7 (IC₅₀ 1.1 μM), HCT-116 (IC₅₀ 2.6 μM), and HepG2 (IC₅₀ 1.4 μM). Compound 9 was found to be better than the standard drugs, doxorubicin and 5-fluorouracil. These compounds showed anticancer activity through thymidylate synthase inhibition as they displayed significant TS inhibitory activity with IC₅₀ in the range 1.95–4.24 μM, whereas the standard drug, Pemetrexed, showed IC₅₀ 7.26 μM. The antimicrobial results showed that some of the compounds (6, 7, 9, 16, and 17) exhibited good inhibition on Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus). The molecular docking and simulation studies supported the anticancer and antimicrobial data. It can be concluded that the synthesized 1,2,3-triazole tethered thymol-1,3,4-oxadiazole conjugates have both antiproliferative and antimicrobial potential.

Thymidylate synthase (TS) has emerged as a hot spot in cancer treatment, as it is directly involved in DNA synthesis. In the present article, nine hybrids containing 1,2,3-triazole and 1,3,4-oxadiazole moieties (6–14) were synthesized and evaluated for anticancer and in vitro thymidylate synthase activities. According to in silico pharmacokinetic studies, the synthesized hybrids exhibited good drug likeness properties and bioavailability. The cytotoxicity results indicated that compounds 12 and 13 exhibited remarkable inhibition on the tested Michigan Cancer Foundation (MCF-7) and Human colorectal Carcinoma (HCT-116) cell lines. Compound 12 showed four-fold inhibition to a standard drug, 5-fluoruracil, and comparable inhibition to tamoxifen, whereas compound 13 exerted five-fold activity of tamoxifen and 24-fold activity of 5-fluorouracil for MCF-7 cells. Compounds 12 and 13 inhibited thymidylate synthase enzyme, with an half maximal inhibitory concentration, IC₅₀ of 2.52 µM and 4.38 µM, while a standard drug, pemetrexed, showed IC₅₀ = 6.75 µM. The molecular docking data of compounds 12 and 13 were found to be in support of biological activities data. In conclusion, hybrids (12 and 13) may inhibit thymidylate synthase enzyme, which could play a significant role as a chemotherapeutic agent.